Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

  • Revenue in USD (TTM)49.88bn
  • Net income in USD7.96bn
  • Incorporated1996
  • Employees110.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
NOVN:SWX since
Cadent TherapeuticsAnnounced17 Dec 202017 Dec 2020Announced-0.04%770.00m
Vedere Bio IncDeal completed30 Sep 202030 Sep 2020Deal completed-0.01%280.00m
Data delayed at least 15 minutes, as of May 14 2021 16:37 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Takeda Pharmaceutical Co Ltd29.24bn3.44bn53.96bn47.50k15.591.136.311.85239.95239.952,037.443,308.930.24851.314.15--2.921.973.452.4468.9168.6411.767.
Chugai Pharmaceutical Co Ltd7.10bn1.93bn63.26bn7.56k32.186.89--8.91128.02128.02471.90597.670.70891.494.03102,758,300.0019.2312.7622.4215.2165.5457.6727.1319.273.86483.150.0046.7614.689.5536.2928.5719.4425.98
Bayer AG49.64bn-18.03bn68.06bn99.33k--1.62--1.37-15.11-10.0741.6335.210.33481.873.00410,727.60-12.15-0.9407-15.41-1.2053.0960.72-36.30-2.480.87599.860.5521---4.93-2.12-751.15---0.7993-4.06
Novartis AG (ADR)49.88bn7.96bn219.20bn110.00k25.593.9515.254.393.483.4821.8022.500.40752.195.94471,520.106.506.418.688.0170.5869.3915.9517.790.504--0.427781.092.62-0.183813.022.84-5.912.98
Roche Holding AG64.71bn15.86bn294.41bn101.47k18.377.1213.524.5516.5216.5267.4342.600.68932.405.66574,809.1017.8114.8226.6322.0872.7471.3925.8420.921.0141.000.263366.01-5.113.915.9110.0313.842.36
Data as of May 15 2021. Currency figures normalised to Novartis AG's reporting currency: US Dollar USD

Institutional shareholders

4.83%Per cent of shares held by top holders
HolderShares% Held
Dodge & Coxas of 31 Mar 202121.67m0.88%
PRIMECAP Management Co.as of 31 Mar 202120.54m0.83%
Loomis, Sayles & Co. LPas of 31 Dec 202020.12m0.82%
Optiver US LLCas of 31 Mar 202113.88m0.56%
Fisher Asset Management LLCas of 31 Mar 20219.66m0.39%
Franklin Mutual Advisers LLCas of 31 Mar 20218.34m0.34%
Aristotle Capital Management LLCas of 31 Dec 20207.12m0.29%
Managed Account Advisors LLCas of 31 Mar 20217.01m0.28%
Boston Partners Global Investors, Inc.as of 31 Mar 20215.86m0.24%
UBS Financial Services, Inc.as of 31 Mar 20215.02m0.20%
More ▼
Data from 31 Dec 2020 - 31 Mar 2021Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.